GoAI
Get started
Tianda Pharmaceuticals Limited logo

Tianda Pharmaceuticals Limited

0455.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$0.111

−HK$0.016 · -12.60%

Aug 21, 11:35 AM HKT

0455.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September 2012, focuses on the research, development, manufacturing, and distribution of a wide array of pharmaceutical, biotechnology, and healthcare products. Its commercial reach extends across Mainland China, Hong Kong, and Australia. The company's diverse portfolio includes traditional Chinese medicines, chemical drugs, biological products, and medical appliances. These offerings target numerous therapeutic areas, such as cardio-cerebrovascular health, pediatric care, anti-flu and respiratory conditions, anti-infection, detoxification, and urological disorders. Health supplements are specifically marketed under the "Herb Valley" and "Tuokang" brand names. Furthermore, Tianda Pharmaceuticals is involved in the wholesale and retail of Chinese herbal medicines, traditional Chinese medicine (TCM) decoction pieces, and other Chinese medicinal products, provides Chinese medical services, and trades agricultural by-products.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Wen Quan Fang
Listed since
Mar 30, 1992
Employees
613

Market position

Day range

Current HK$0.111

52-week range

Current HK$0.111

Open
HK$0.128
Previous close
HK$0.127
Volume
4K
0.06× average
Average volume
62.24K
Average daily volume
Market cap
238.65M HKD
Beta
-0.06
Market reference 1
50-day average
HK$0.0988
+12.35% above average
200-day average
HK$0.1038
+6.93% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
345.21M HKD
P/E (TTM)
-6.49×
P/B (TTM)
0.52×
P/S (TTM)
1.28×
EV / EBITDA
-14.14×
Earnings yield
-25.24%
Free cash flow yield
1.01%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
41.18%
Operating margin
-11.01%
Net margin
-19.73%
Return on equity
-15.33%
Return on assets
-9.36%
Return on invested capital
-9.07%

Financial health

Debt / equity
0.29×
Current ratio
0.83×
Altman Z-score
0.91
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends55%27%-1%-29%Gross margin, FY2021: 47.30%Gross margin, FY2022: 46.01%Gross margin, FY2023: 48.02%Gross margin, FY2024: 46.08%Gross margin, FY2025: 41.28%Operating margin, FY2021: -7.64%Operating margin, FY2022: -12.83%Operating margin, FY2023: -5.45%Operating margin, FY2024: -16.41%Operating margin, FY2025: -16.75%Net margin, FY2021: -4.25%Net margin, FY2022: -9.99%Net margin, FY2023: -4.54%Net margin, FY2024: -18.60%Net margin, FY2025: -21.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 47.30%. Gross margin FY2022 46.01%. Gross margin FY2023 48.02%. Gross margin FY2024 46.08%. Gross margin FY2025 41.28%. Operating margin FY2021 -7.64%. Operating margin FY2022 -12.83%. Operating margin FY2023 -5.45%. Operating margin FY2024 -16.41%. Operating margin FY2025 -16.75%. Net margin FY2021 -4.25%. Net margin FY2022 -9.99%. Net margin FY2023 -4.54%. Net margin FY2024 -18.60%. Net margin FY2025 -21.67%.

Income trends

Revenue

322.95M HKD-2.12%

Operating income

−54.09M HKD+0.11%

Net income

−70M HKD-14.06%
Income trends across reported periods608.38M HKD361.64M HKD114.91M HKD−131.83M HKDRevenue, FY2021: 509.96M HKDRevenue, FY2022: 546.69M HKDRevenue, FY2023: 532.09M HKDRevenue, FY2024: 329.94M HKDRevenue, FY2025: 322.95M HKDOperating income, FY2021: −38.97M HKDOperating income, FY2022: −70.14M HKDOperating income, FY2023: −29.02M HKDOperating income, FY2024: −54.15M HKDOperating income, FY2025: −54.09M HKDNet income, FY2021: −21.67M HKDNet income, FY2022: −54.64M HKDNet income, FY2023: −24.16M HKDNet income, FY2024: −61.37M HKDNet income, FY2025: −70M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 509.96M HKD. Revenue FY2022 546.69M HKD. Revenue FY2023 532.09M HKD. Revenue FY2024 329.94M HKD. Revenue FY2025 322.95M HKD. Operating income FY2021 −38.97M HKD. Operating income FY2022 −70.14M HKD. Operating income FY2023 −29.02M HKD. Operating income FY2024 −54.15M HKD. Operating income FY2025 −54.09M HKD. Net income FY2021 −21.67M HKD. Net income FY2022 −54.64M HKD. Net income FY2023 −24.16M HKD. Net income FY2024 −61.37M HKD. Net income FY2025 −70M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue322.95M HKD329.94M HKD532.09M HKD546.69M HKD509.96M HKD
Cost of goods sold189.64M HKD177.91M HKD276.56M HKD295.17M HKD268.73M HKD
Gross profit133.31M HKD152.02M HKD255.53M HKD251.52M HKD241.22M HKD
Research and development8.33M HKD13.28M HKD13.11M HKD36.15M HKD15.86M HKD
Selling, general, and administrative179.07M HKD192.89M HKD271.45M HKD285.52M HKD269.46M HKD
Operating expenses187.4M HKD206.17M HKD284.56M HKD321.66M HKD283.25M HKD
Interest income——3.03M HKD4.34M HKD2.97M HKD
Interest expense—4.85M HKD4.95M HKD7.49M HKD725.24K HKD
Depreciation and amortization29.68M HKD38.23M HKD36.41M HKD50.25M HKD22.15M HKD
Operating income−54.09M HKD−54.15M HKD−29.02M HKD−70.14M HKD−38.97M HKD
Net income−70M HKD−61.37M HKD−24.16M HKD−54.64M HKD−21.67M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.02

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0-0.02-0.04-0.06Q3 '21Q1 '22Q4 '22Q2 '23Q2 '23Q4 '23Q3 '24Q1 '25
Q3 2021, reported Sep 30, 2021: actual -0.008, estimate —, surprise —, Comparison unavailable. Q1 2022, reported Mar 31, 2022: actual -0.001, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 26, 2022: actual -0.024, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 28, 2023: actual -0.001, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual -0.002, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Dec 31, 2023: actual -0.009, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual -0.013, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual -0.016, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates414.41M320.37M226.33M132.29MQ3 '21Q1 '22Q4 '22Q2 '23Q2 '23Q4 '23Q3 '24Q1 '25
Q3 2021, reported Sep 30, 2021: actual 236.52M HKD, estimate —, surprise —, Comparison unavailable. Q1 2022, reported Mar 31, 2022: actual 273.44M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 26, 2022: actual 394.95M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 28, 2023: actual 151.74M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual 303.48M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Dec 31, 2023: actual 228.61M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 156.07M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 173.86M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.0052

2024 complete year+300.0% since 2020

Corporate action history

Dividend

Ex-dividend Jun 13, 2024

HK$0.0026

Irregular

Record Jun 14, 2024 · Payment Jun 28, 2024

Dividend

Ex-dividend May 31, 2024

HK$0.0026

Annual

Record Jun 3, 2024 · Payment Jun 28, 2024

Dividend

Ex-dividend Jun 29, 2023

HK$0.0026

Annual

Record Jul 3, 2023 · Payment Jul 14, 2023

Dividend

Ex-dividend Sep 2, 2022

HK$0.0082

Special

Record Sep 5, 2022 · Payment Sep 16, 2022

Dividend

Ex-dividend Sep 3, 2021

HK$0.0026

Annual

Record Sep 7, 2021 · Payment Sep 23, 2021

Dividend

Ex-dividend Sep 3, 2020

HK$0.0013

Annual

Record Sep 7, 2020 · Payment Sep 23, 2020

0455.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 0455.HK

research.disclaimer